CYTK Q3 2022 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-53.7% YoY

Gross Profit

-$60M-2394.4% margin

Operating Income

-$108M-4311.8% margin

Net Income

-$142M-5658.4% margin

EPS (Diluted)

$-1.88

QoQ Revenue Growth

-97.2%

Cash Flow

Operating Cash Flow

-$82M

Free Cash Flow

-$88M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$1.1B

Stockholders' Equity

-$16M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$5M	-53.7%
Gross Profit	-$60M	-$43M	-40.0%
Operating Income	-$108M	-$69M	-56.7%
Net Income	-$142M	-$76M	-87.0%

Revenue Segments

Research And Development

$3M100%